BackSierra Oncology Overview

Sierra Oncology Other Current Liabilities

Latest other current liabilities for SRRA: $11M.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$10.96M
78.28% YoYΔ $4.81M vs prior year quarter

Peer trimmed avg / median

Loading

Sierra Oncology Other Current Liabilities History

Loading

Sierra Oncology vs. peers: Other Current Liabilities Comparison

Loading

Sierra Oncology Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Sierra Oncology (SRRA) FAQ

Sierra Oncology's other current liabilities stands at $11M as of March 2022. That compares with $6.2M in the prior-year period — up 78.3% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Sierra Oncology reported $11M in other current liabilities versus $6.2M a year earlier — a 78.3% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $6.2M in the prior-year period — up 78.3% year over year. Sustained growth in other current liabilities can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Sierra Oncology's other current liabilities evolved across reporting periods, while the comparison chart places SRRA next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, other current liabilities is commonly used to spot outliers. Sierra Oncology's reading of $11M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.